Fryderyk Lorenz

427 total citations
18 papers, 239 citations indexed

About

Fryderyk Lorenz is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Fryderyk Lorenz has authored 18 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 6 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Fryderyk Lorenz's work include Acute Myeloid Leukemia Research (10 papers), Lysosomal Storage Disorders Research (4 papers) and Vascular Tumors and Angiosarcomas (2 papers). Fryderyk Lorenz is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Lysosomal Storage Disorders Research (4 papers) and Vascular Tumors and Angiosarcomas (2 papers). Fryderyk Lorenz collaborates with scholars based in Sweden, Poland and United States. Fryderyk Lorenz's co-authors include Anders Wåhlin, Martin Jädersten, Petar Antunović, Maciej Machaczka, Sören Lehmann, Monika Klimkowska, Hege Garelius, Eva Hellström‐Lindberg, Martin Höglund and Björn E. Wahlin and has published in prestigious journals such as Blood, Scientific Reports and British Journal of Haematology.

In The Last Decade

Fryderyk Lorenz

18 papers receiving 237 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fryderyk Lorenz Sweden 10 193 79 66 35 30 18 239
Diego V. Clé Brazil 9 79 0.4× 53 0.7× 52 0.8× 53 1.5× 25 0.8× 21 190
Juan Manuel Alonso‐Domínguez Spain 10 106 0.5× 75 0.9× 78 1.2× 20 0.6× 30 1.0× 40 242
Lars‐Olof Mügge Germany 8 182 0.9× 45 0.6× 73 1.1× 13 0.4× 26 0.9× 21 224
Takanobu Morishita Japan 11 100 0.5× 43 0.5× 107 1.6× 16 0.5× 42 1.4× 37 268
Agnieszka Tomaszewska Poland 8 76 0.4× 59 0.7× 35 0.5× 19 0.5× 53 1.8× 27 194
Uroš Markovic Italy 8 95 0.5× 33 0.4× 60 0.9× 24 0.7× 32 1.1× 36 188
Hiraku Mori Japan 9 144 0.7× 91 1.2× 59 0.9× 12 0.3× 11 0.4× 23 219
Haifaa Abdulhaq United States 7 152 0.8× 89 1.1× 79 1.2× 11 0.3× 6 0.2× 29 225
Geetha Puthenveetil United States 8 105 0.5× 134 1.7× 165 2.5× 46 1.3× 51 1.7× 16 352
Magnun Nueldo Nunes Santos Brazil 11 192 1.0× 266 3.4× 76 1.2× 42 1.2× 32 1.1× 41 341

Countries citing papers authored by Fryderyk Lorenz

Since Specialization
Citations

This map shows the geographic impact of Fryderyk Lorenz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fryderyk Lorenz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fryderyk Lorenz more than expected).

Fields of papers citing papers by Fryderyk Lorenz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fryderyk Lorenz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fryderyk Lorenz. The network helps show where Fryderyk Lorenz may publish in the future.

Co-authorship network of co-authors of Fryderyk Lorenz

This figure shows the co-authorship network connecting the top 25 collaborators of Fryderyk Lorenz. A scholar is included among the top collaborators of Fryderyk Lorenz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fryderyk Lorenz. Fryderyk Lorenz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Nilsson, Lars, Magnus Tobiasson, Martin Jädersten, et al.. (2025). Influence of Cytogenetics on the Outcome of Patients With High‐Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. Genes Chromosomes and Cancer. 64(2). e70029–e70029. 1 indexed citations
2.
Eriksson, Anna, Martin Jädersten, Vladimir Lazarević, et al.. (2022). A risk score based on real-world data to predict early death in acute promyelocytic leukemia. Haematologica. 107(7). 1528–1537. 12 indexed citations
3.
Creignou, Maria, Elsa Bernard, Michael J. Crowther, et al.. (2022). Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes. Blood. 140(Supplement 1). 6968–6970. 1 indexed citations
4.
Rosso, Aldana, Gunnar Juliusson, Fryderyk Lorenz, et al.. (2021). Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study. Leukemia & lymphoma. 62(8). 1973–1981. 4 indexed citations
5.
Orsmark‐Pietras, Christina, Niklas Landberg, Fryderyk Lorenz, et al.. (2021). Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR‐ABL1, a Swedish population‐based study. Genes Chromosomes and Cancer. 60(6). 426–433. 8 indexed citations
6.
Juliusson, Gunnar, Martin Jädersten, Stefan Deneberg, et al.. (2020). The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Advances. 4(6). 1094–1101. 47 indexed citations
7.
Garelius, Hege, Fryderyk Lorenz, Lars Nilsson, et al.. (2020). Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population‐based study. British Journal of Haematology. 192(3). 474–483. 9 indexed citations
8.
Folkvaljon, Yasin, Johan Sundberg, Mats Lambe, et al.. (2018). Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register. British Journal of Haematology. 181(5). 614–627. 30 indexed citations
9.
10.
Folkvaljon, Yasin, J. Sundberg, Mats Lambe, et al.. (2016). VALIDATION OF PROGNOSTIC SCORING SYSTEMS FOR MYELODYSPLASTIC SYNDROMES IN THE SWEDISH MDS-REGISTER. Haematologica. 101. 243–243. 1 indexed citations
11.
Lorenz, Fryderyk, Monika Klimkowska, Soheir Beshara, et al.. (2016). Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. Blood Cells Molecules and Diseases. 68. 35–42. 23 indexed citations
12.
Lorenz, Fryderyk, Stefan L. Marklund, Mårten Werner, et al.. (2015). Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation. Scientific Reports. 5(1). 7920–7920. 11 indexed citations
13.
Lorenz, Fryderyk, et al.. (2014). Długotrwała pancytopenia po chemioterapii jako objaw demaskujący chorobę Gauchera u pacjentki z rakiem płuca. Acta Haematologica Polonica. 45(3). 294–300. 3 indexed citations
14.
Svensson, Tobias, Onima Chowdhury, Hege Garelius, et al.. (2014). A pilot phase I dose finding safety study of the thrombopoietin‐receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. European Journal Of Haematology. 93(5). 439–445. 28 indexed citations
15.
Lorenz, Fryderyk, Aleksander B. Skotnicki, & Maciej Machaczka. (2014). Wartość diagnostyczna i zastosowanie kliniczne biomarkerów oraz ferrytynemii w chorobie Gauchera. Acta Haematologica Polonica. 45(2). 149–154. 1 indexed citations
16.
Machaczka, Maciej, et al.. (2013). Recurrent pulmonary aspergillosis and mycobacterial infection in an unsplenectomized patient with type 1 Gaucher disease. Upsala Journal of Medical Sciences. 119(1). 44–49. 10 indexed citations
17.
Li, Xingru, et al.. (2012). Reduction in WT1 Gene Expression During Early Treatment Predicts the Outcome in Patients With Acute Myeloid Leukemia. Diagnostic Molecular Pathology. 21(4). 225–233. 17 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diego V. Clé Breakdown of academic impact, for papers by Juan Manuel Alonso‐Domínguez Breakdown of academic impact, for papers by Lars‐Olof Mügge Breakdown of academic impact, for papers by Takanobu Morishita Breakdown of academic impact, for papers by Agnieszka Tomaszewska Breakdown of academic impact, for papers by Uroš Markovic Breakdown of academic impact, for papers by Hiraku Mori Breakdown of academic impact, for papers by Haifaa Abdulhaq Breakdown of academic impact, for papers by Geetha Puthenveetil Breakdown of academic impact, for papers by Magnun Nueldo Nunes Santos
Rankless by CCL
2026